DEVELOPMENT OF BLOOD-BASED ALZHEIMER’S PROGNOSTIC PROPELS DIADEM TO FINALIST STATUS FOR BOTH THE GAETANO MARZOTTO COMPANY PRIZE AND 2030 SOCIAL IMPACT SPECIAL PRIZE

—Prestigious Awards Celebrate Entrepreneurial Company Innovation and Pioneering New Products Supporting UN Sustainable Development Goals —

—Diadem’s Minimally Invasive Blood-Based AlzoSure® Prognostic Test for Early Alzheimer’s Disease Selected for Potential to Help Transform Management of this Devastating Global Disorder—

—Diadem Also Provides Update on Intellectual Property Status of the AlzoSure Technology—

Milan, ITALY – November 16, 2020 – pool of 600 applicants. The companies were analyzed by experts representing relevant public, private, financial, technological and specialist sectors. Diadem was one of five finalist companies for the Gaetano Marzotto Company Prize and one of six finalists for the Gaetano Marzotto 2030 Social Impact Special Prize.

“We are incredibly honored to be selected as a finalist for both the Gaetano Marzotto Company Prize and the inaugural Gaetano Marzotto 2030 Social Impact Special Prize, which highlights young companies whose products have the potential to advance the UN Sustainable Development Goals and reduce inequality,” said Paul Kinnon, CEO of Diadem. “Alzheimer’s disease and other dementias afflict more than 50 million people worldwide. Our revolutionary AlzoSure prognostic test could transform Alzheimer’s disease management, enabling effective interventions much earlier in the disease process. Importantly, as a blood-based, non-invasive biomarker assay, we expect AlzoSure to be widely available to older populations around the globe, combining great clinical and commercial potential with exceptional accessibility.”

Diadem also provided an update on its intellectual property. Diadem has taken steps to patent the innovative AlzoSure technology, including its proprietary antibody and the actual process for the assay. Patents have been filed in Italy, the US and other regions including China and Japan. US Patent 10,183,990 B2, which issued last year, covers Diadem’s antibody, immunodiagnostic kit and associated in vitro methods of diagnosing Alzheimer’s disease and/or the predisposition to develop Alzheimer’s disease. It covers the company’s game-changing plasma-based technology that measures conformational changes in the p-53 pathway, targeting Unfolded p-53, which is over-expressed in Alzheimer’s patients, and applies an analytical method that includes a proprietary antibody and target sequences developed by Diadem. A similar patent, EP 3 201 234 B1, issued in the European Union in 2018.

Mr. Kinnon commented, “Diadem plans to continue to aggressively protect our technology and products by filing further patents globally and prosecuting those currently in process. We believe our AlzoSure technology can help transform the prediction and treatment of early Alzheimer’s disease, and we are committed to protecting the innovative intellectual property that makes the test possible.”

Diadem’s AlzoSure is a plasma-based biomarker test that has been validated in early studies to accurately predict the probability a patient with mild cognitive impairment will progress to Alzheimer’s disease. Further clinical studies are underway, and the company plans a global launch in collaboration with strategic partners in 2021.

For more information on the Gaetano Marzotto Prizes, visit www.premiogaetanomarzotto.it/en/homepage/